Create site
I want to Me website
@ADVMAKER@

EUROPEAN STANDARDS OF TREATMENT MYELOID LEUKEMIA

15.06.2016

The other day in Moscow was held a panel discussion on the topic «Evolution of treatment of chronic myeloid leukaemia (CML) in Russia - harmonization with the European research community», dedicated to the release of the updated European guidelines for the treatment of CML and opportunities for application of European approaches to the treatment of patients with CML in the Russian practice.

Treatment of chronic myeloid leukaemia (CML) is one of the most urgent problems in the Russian Oncohematology. Limited access of patients with CML innovative therapy, insufficient effect of treatment with a single drug - with these and other challenges facing patients with a diagnosis of CML and doctors. How to find the way out of the situation and to extend the life of patients to these and other questions are trying to find answers to the panelists.

Chronic myeloid leukemia (CML) - first oncohematological disease in which revealed a genetic abnormality. The incidence of CML is from 10 to 15 cases per 100,000 people, while not depend on geographical or ethnic characteristics. The average age of patients is from 60 to 65 years. In Russia today there are about 6 000 patients.

Leading Russian and hematologists argue that the situation with the diagnosis, means and treatment of disease has improved significantly. Indeed, until recently, the average life expectancy of people with CML was 4-5 years old, and modern drugs can extend it up to 10-12 years, while the quality of life of the patient remains at a good level.

According to Professor Hellmann, disease respond to therapy with timely diagnosis and operative treatment initiated, and in the absence of positive dynamics in a patient on therapy with one drug, and its replacement is necessary on the other.

In Russia the situation is such that the standard therapy involves the use of first-line drugs, which, in the framework programme 7 nosologies purchased at the expense of the state. However, a third of Russian patients with CML in Russia has been resistant to such treatment or intolerance of drugs, which negatively affects the survival and quality of life of patients. As a result, these patients require therapy with modern preparations of the second line, which, unfortunately, are inaccessible and are not funded by the state. Academician C. G. Savchenko, in turn, noted that proven effective drugs may also be used for treatment of these patients.

As for the state support of patients with CML, C. D. Melik-Guseinov, Director of the Centre for social economy», during his speech noted that the financing of the health system currently has improved, but, unfortunately, not fully cover expenses on current treatment, which cannot but affect drug provision of patients, including those with CML. Also C. D. Melik-Guseinov, presented data showing that in Europe today, about 40% of patients with CML are provided with second-line drugs. In Russia this percentage is much lower.

By the end of the panel discussion was the conclusion about the necessity of harmonization of the Russian practice with the European experience in the treatment of CML to increase access to modern innovative drug therapies, increase survival and preservation of quality of life of patients at a high level. Participants also noted that the transition to European standards of treatment of CML in Russia - is a joint work of doctors, and state and patient communities.

Author: Oksana Lisenkova 

Comments (0)Views (30)


Registered
Anonymous
Login Register
Password Remind password